* Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected
to show a rise in quarterly revenue when it reports results on
November 7 (estimated).
* The Florham Park New Jersey-based company is expected to
report
revenue of $200 thousand, according to the mean estimate from 5
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Phathom
Pharmaceuticals
Inc is for a loss of $1.32 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $34, above its last closing price
of $10.08.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.99 -1.03 -1.33 Missed -29.1
Mar. 31 2022 -0.98 -0.97 -1.07 Missed -10.5
Dec. 31 2021 -1.05 -1.03 -0.95 Beat 7.6
Sep. 30 2021 -1.01 -0.98 -0.98 Met 0
Jun. -1.07 -1.07 -1.00 Beat 6.4
30 2021
Mar. 31 2021 -1.18 -1.19 -0.96 Beat 19.2
Dec. 31 2020 -0.99 -1.01 -1.58 Missed -56.2
Sep. 30 2020 -0.67 -0.67 -1.02 Missed -51.5
This summary was machine generated November 4 at 17:44 GMT. All
figures in US dollars unless otherwise stated